β-Blocker pharmacogenetics in heart failure

被引：35

作者：

Shin, Jaekyu ^{[1
]}

Johnson, Julie A. ^{[1
]}

机构：

[1] Univ Florida, Dept Pharm Practice, Coll Pharm, Ctr Pharmacogenet, Gainesville, FL 32610 USA

来源：

HEART FAILURE REVIEWS | 2010年 / 15卷 / 03期

关键词：

Pharmacogenetics; beta-Blockers; Heart failure; Metoprolol; ADRB1; ADRB2; HUMAN BETA(2)-ADRENERGIC RECEPTOR; VENTRICULAR EJECTION FRACTION; ENZYME DELETION POLYMORPHISM; BETA(1)-ADRENERGIC RECEPTOR; ALPHA(2C)-ADRENERGIC RECEPTORS; SYNERGISTIC POLYMORPHISMS; CYTOCHROME-P450; 2D6; METOPROLOL CR/XL; CYP2D6; GENOTYPE; THERAPY;

D O I：

10.1007/s10741-008-9094-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

beta-Blockers (metoprolol, bisoprolol, and carvedilol) are a cornerstone of heart failure (HF) treatment. However, it is well recognized that responses to a beta-blocker are variable among patients with HF. Numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to a beta-blocker, including left ventricular ejection fraction improvement, survival, and hospitalization due to HF exacerbation. This review summarizes the pharmacogenetic data for beta-blockers in patients with HF and discusses the potential implications of beta-blocker pharmacogenetics for HF patients.

引用

页码：187 / 196

页数：10

共 55 条

[1] Titration of β-blockers in heart failure -: How to maximize benefit while minimizing adverse events [J].

Basile, JN .

POSTGRADUATE MEDICINE, 2003, 113 (03) :63-70

[2]

Brodde OE, 2003, ARZNEIMITTELFORSCH, V53, P814

[3] EFFECT OF VASODILATOR THERAPY ON MORTALITY IN CHRONIC CONGESTIVE-HEART-FAILURE - RESULTS OF A VETERANS-ADMINISTRATION COOPERATIVE STUDY [J].

COHN, JN ;

ARCHIBALD, DG ;

ZIESCHE, S ;

FRANCIOSA, JA ;

HARSTON, WE ;

TRISTANI, FE ;

DUNKMAN, WB ;

JACOBS, W ;

FRANCIS, GS ;

FLOHR, KH ;

GOLDMAN, S ;

COBB, FR ;

SHAH, PM ;

SAUNDERS, R ;

FLETCHER, RD ;

LOEB, HS ;

HUGHES, VC ;

BAKER, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (24) :1547-1552

[4] The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure [J].

Curtis, JP ;

Sokol, SI ;

Wang, YF ;

Rathore, SS ;

Ko, DT ;

Jadbabaie, F ;

Portnay, EL ;

Marshalko, SJ ;

Radford, MJ ;

Krumholz, HM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (04) :736-742

[5] Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure [J].

de Groote, P ;

Helbecque, N ;

Lamblin, N ;

Hermant, X ;

Mc Fadden, E ;

Foucher-Hossein, C ;

Amouyel, P ;

Dallongeville, J ;

Bauters, C .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (03) :137-142

[6] Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure [J].

de Groote, P ;

Helbecque, N ;

Lamblin, N ;

Hermant, X ;

Amouyel, P ;

Bauters, C ;

Dallongeville, J .

EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (01) :17-21

[7] The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization [J].

Dishy, V ;

Sofowora, GG ;

Xie, HG ;

Kim, RB ;

Byrne, DW ;

Stein, CM ;

Wood, AJJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1030-1035

[8] Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [J].

Drysdale, CM ;

McGraw, DW ;

Stack, CB ;

Stephens, JC ;

Judson, RS ;

Nandabalan, K ;

Arnold, K ;

Ruano, G ;

Liggett, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10483-10488

[9]

Eichhorn E, 2001, NEW ENGL J MED, V344, P1659

[10] Carvedilol [J].

Frishman, WH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (24) :1759-1765

← 1 2 3 4 5 6 →